-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
-
Summary
-
Adaptimmune Therapeutics PLC quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2013 to 2023.
- Adaptimmune Therapeutics PLC Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $3.05M, a 4.05% decline year-over-year.
- Adaptimmune Therapeutics PLC Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $12.3M, a 2.78% decline year-over-year.
- Adaptimmune Therapeutics PLC annual Share-based Payment Arrangement, Expense for 2023 was $11.8M, a 35.5% decline from 2022.
- Adaptimmune Therapeutics PLC annual Share-based Payment Arrangement, Expense for 2022 was $18.2M, a 11.6% decline from 2021.
- Adaptimmune Therapeutics PLC annual Share-based Payment Arrangement, Expense for 2021 was $20.6M, a 98.1% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)